Literature DB >> 30094265

DIAMOND study: an additional evidence of the interest of being proactive in IBD.

Xavier Roblin1, Mathurin Flamant2.   

Abstract

Year:  2018        PMID: 30094265      PMCID: PMC6064788          DOI: 10.21037/atm.2018.06.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  14 in total

Review 1.  American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

Authors:  Niels Vande Casteele; Hans Herfarth; Jeffry Katz; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-07-31       Impact factor: 22.682

2.  Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Authors:  Konstantinos Papamichael; Filip Baert; Sophie Tops; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Ann Gils; Marc Ferrante
Journal:  J Crohns Colitis       Date:  2016-07-11       Impact factor: 9.071

3.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.

Authors:  Filip Baert; Venkateswarlu Kondragunta; Steven Lockton; Niels Vande Casteele; Scott Hauenstein; Sharat Singh; Konstantinos Karmiris; Marc Ferrante; Ann Gils; Séverine Vermeire
Journal:  Gut       Date:  2015-04-10       Impact factor: 23.059

5.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Authors:  Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens
Journal:  Lancet       Date:  2017-10-31       Impact factor: 79.321

6.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

Authors:  Takayuki Matsumoto; Satoshi Motoya; Kenji Watanabe; Tadakazu Hisamatsu; Hiroshi Nakase; Naoki Yoshimura; Tetsuya Ishida; Shingo Kato; Tomoo Nakagawa; Motohiro Esaki; Masakazu Nagahori; Toshiyuki Matsui; Yuji Naito; Takanori Kanai; Yasuo Suzuki; Masanori Nojima; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2016-08-26       Impact factor: 9.071

7.  Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.

Authors:  Y Mazor; R Almog; U Kopylov; D Ben Hur; A Blatt; A Dahan; M Waterman; S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2014-07-15       Impact factor: 8.171

Review 8.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

10.  Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

Authors:  Bella Ungar; Idan Levy; Yarden Yavne; Miri Yavzori; Orit Picard; Ella Fudim; Ronen Loebstein; Yehuda Chowers; Rami Eliakim; Uri Kopylov; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-29       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.